ArticleJTO clinical and research reports2023

Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.

Masaki Ishida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.